Clinical trials
HIV-1-infection clinical trials
Below are recruiting hiv-1-infection clinical trials, each written for real people, not researchers. We’re tracking 89 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06902142Recruiting
HIV treatment study with Bictegravir medication monitoring
This study looks at how well HIV-1 patients take their medication (bictegravir/emtricitabine/tenofovir) and how that relates to how well the virus is controlled. It uses a special pill bottle cap that records when the bottle is opened, so the research team can see if the medicine is being taken as prescribed.
CaenAges 18 years+ - NCT06517693RecruitingPhase 1
HIV antibody safety study for newborns at risk
This study tests whether giving a combination of two lab-made antibodies (PGT121.414.LS and VRC07-523LS) to newborns exposed to HIV during pregnancy is safe and how the body processes them. It may help protect infants from getting HIV after birth.
Los Angeles, CaliforniaAges Up to 3 days - NCT07392372RecruitingPhase 1
Testing the safety of BNT351 in people with and without HIV
This trial tests a new antibody called BNT351 to see if it is safe and how it affects the immune system. It is for adults who either do not have HIV, or have HIV and are not currently on HIV medications.
Chicago, IllinoisAges 18–65 - NCT07202546RecruitingPhase 2
New oral HIV drug trial for people new to treatment
This trial tests a new oral HIV medication (VH4524184) in people who have never taken HIV treatment before. It looks at how well the drug controls the virus and how safe it is.
Bakersfield, CaliforniaAges 18 years+ - NCT04098315Recruiting
HIV drug-resistance patient registry study for people 14+
This study is a registry (a way to collect and organize information) for people living with HIV who have drug-resistant virus. It may help researchers better understand how resistant HIV behaves and how to manage treatment over time.
Milan, MIAges 14 years+ - NCT04160455Recruiting
Study of GALIG proteins in adults with HIV on or off treatment
This study looks at how “GALIG” gene products affect the body’s internal recycling process (called autophagy) in people living with HIV. It may help researchers understand differences between people on HIV treatment, starting treatment, or not currently taking it.
OrléansAges 18 years+ - NCT04174755Recruiting
Semaglutide for weight loss in adults with HIV
This trial studies whether semaglutide (a diabetes-type weight-loss injection) helps adults with HIV lose weight. It also checks that it’s safe for people whose HIV is well controlled on regular treatment.
Dublin, DublinAges 18 years+ - NCT04513626RecruitingPhase 2
HIV trial testing doravirine plus raltegravir in adults
This Phase 2 trial studies whether switching to a combination of doravirine and raltegravir can safely maintain control of HIV in adults whose virus is already well suppressed. It may help people who are currently on stable HIV treatment and are not resistant to these specific medicines.
Paris, Île-de-France RegionAges 18 years+ - NCT04648046RecruitingPhase 1/Phase 2
CAR-T cell treatment for HIV infection
This early-phase study tests whether CAR-T cells (immune cells modified to recognize HIV) can help control HIV. You may be asked to briefly pause HIV medicines to see how well the treatment controls the virus.
Sacramento, CaliforniaAges 18–65 - NCT04883255RecruitingEarly Phase 1
Study cannabis effects on brain function in adults with HIV
This early-phase study looks at how cannabis (and the body’s cannabinoid system) may affect thinking and brain-related measures in people with HIV. You may be asked to avoid cannabis and complete several brain and health assessments to see how these factors relate.
San Diego, CaliforniaAges 18–65 - NCT07266831RecruitingPhase 2/Phase 3
Study of islatravir and ulonivirine for new HIV patients
This trial tests two new HIV medications, islatravir and ulonivirine, in people who have never taken HIV treatment before. It aims to see if this combination can safely control the virus.
Los Angeles, CaliforniaAges 18 years+ - NCT05215704Recruiting
Lab study of dormant HIV using samples from you
This trial collects blood samples from people living with HIV to study dormant (inactive) HIV cells in the lab. The goal is to better understand how to target these hidden cells as part of an eventual cure.
RotterdamAges 18 years+ - NCT05590455RecruitingPhase 2
Testing a TNF-blocking drug to reduce death in HIV and TB meningitis
This Phase 2 trial studies whether a TNF-blocking medicine can lower the risk of death in people with HIV who also have TB meningitis. You would receive standard TB meningitis treatment plus the study drug, if you meet the criteria.
Rio de JaneiroAges 18 years+ - NCT05652088Recruiting
Study gut immune tissue in HIV cure efforts
This study looks at how immune tissue in the gut may be involved in curing HIV. You may be asked to have two colonoscopies while on an HIV “cure-related” treatment, so researchers can collect tissue samples to understand what’s happening in your body.
New York, New YorkAges 18–75 - NCT07476339RecruitingPhase 4
Returning to HIV Care with Biktarvy
This trial tests the medication Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) for people with HIV who have stopped taking their antiretroviral therapy (ART) for at least 12 weeks and are ready to restart treatment. It aims to see how well the medication works when restarting care.
Clearwater, FloridaAges 18 years+ - NCT06492187Recruiting
Survey to see if you qualify for infectious disease studies
This trial is a quick survey to see if you might be eligible for future infectious disease studies. It helps researchers understand your health background and find the right study for you.
Brooklyn, New YorkAges 18 years+ - NCT06554717RecruitingPhase 2
Tesamorelin and exercise for physical function in HIV
This study tests whether adding tesamorelin to an exercise program helps older adults with HIV improve their physical function and reduce belly fat. It is designed for people who are mostly sedentary and show early signs of frailty.
Aurora, ColoradoAges 50–80 - NCT07186244Recruiting
HIV Prevention Study for People Starting or Taking PrEP
This study is for people who are HIV-negative and want to take PrEP (a daily pill that prevents HIV). It will help researchers learn more about how to best support people taking PrEP in real-world settings.
Chieti, AbruzzoAges 18 years+ - NCT07275606RecruitingPhase 1/Phase 2
Testing HIV prevention medicine cabotegravir in newborns
This study tests a long-acting injectable HIV prevention medicine called cabotegravir in newborn babies who were exposed to HIV. The goal is to see if it can help protect them from getting HIV.
Parow ValleyAges Up to 1 week - NCT07342491RecruitingPhase 1
Testing dasatinib to shrink HIV reservoir
This trial tests whether the drug dasatinib can reduce the hidden HIV reservoir in people who have had their virus well-controlled on HIV medications for a long time. It may help move toward a cure by targeting the cells where HIV hides.
Chicago, IllinoisAges 18 years+ - NCT07370649Recruiting
Long-acting HIV injectable study for subtype A6
This study looks back at medical records of people with HIV-1 who have received a long-acting injectable treatment called cabotegravir plus rilpivirine. It aims to see how well this treatment works for people with a specific HIV subtype (A6).
PragueAges 18 years+ - NCT00537966Recruiting
Study of new HIV infections in the Zurich area
This study enrolls people whose HIV infection is very recent or newly diagnosed (within the last few months). The researchers want to better understand early stages of HIV to improve how doctors identify and track new infections.
ZurichAges 18 years+ - NCT07293559Recruiting
Understanding infant feeding choices in women with HIV
This study looks at how women with HIV decide whether to breastfeed, and what support they get from healthcare providers and family. It aims to learn about their experiences and needs.
Los Angeles, CaliforniaAges Any age - NCT05728996Recruiting
Study of early HIV to guide future care
This study follows people with a very recent HIV infection and collects blood and other samples to learn more about the infection soon after it starts. It may help researchers better understand early HIV and improve future treatments.
Amsterdam, North HollandAges 18 years+
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hiv-1-infection?
- Yes. Clin2 currently lists 89 recruiting hiv-1-infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hiv-1-infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hiv-1-infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.